Effects of romosozumab on the peripheral and axial skeleton in postmenopausal women at high fracture risk: real-world evidence from DXA and HR-pQCT data. (PubMed, Osteoporos Int) - Sep 10, 2026 - "After 12 months of ROMO treatment, aBMD increased significantly at the lumbar spine and total hip, while volumetric BMD, microarchitecture, and strength at the peripheral skeleton did not change or deteriorated."
HEOR • Journal • Real-world evidence • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology
|
|
B van Rietbergen; C E Wyers; J P van den Bergh; M S A M Bevers
|